Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Complex and defined biostructures with the dock-and-lock method.

Rossi EA, Goldenberg DM, Chang CH.

Trends Pharmacol Sci. 2012 Sep;33(9):474-81. doi: 10.1016/j.tips.2012.06.001. Epub 2012 Jun 26.

PMID:
22739259
2.

The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures.

Rossi EA, Goldenberg DM, Chang CH.

Bioconjug Chem. 2012 Mar 21;23(3):309-23. doi: 10.1021/bc2004999. Epub 2012 Jan 10. Review.

PMID:
22168393
3.

Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties.

Rossi EA, Chang CH, Cardillo TM, Goldenberg DM.

Bioconjug Chem. 2013 Jan 16;24(1):63-71. doi: 10.1021/bc300488f. Epub 2012 Dec 21.

PMID:
23116517
4.
5.

Introduction to current and future protein therapeutics: a protein engineering perspective.

Carter PJ.

Exp Cell Res. 2011 May 15;317(9):1261-9. doi: 10.1016/j.yexcr.2011.02.013. Epub 2011 Mar 1. Review.

PMID:
21371474
6.

GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli.

DeFrees S, Wang ZG, Xing R, Scott AE, Wang J, Zopf D, Gouty DL, Sjoberg ER, Panneerselvam K, Brinkman-Van der Linden EC, Bayer RJ, Tarp MA, Clausen H.

Glycobiology. 2006 Sep;16(9):833-43. Epub 2006 May 22.

PMID:
16717104
7.

Site-specific modification of recombinant proteins: a novel platform for modifying glycoproteins expressed in E. coli.

Henderson GE, Isett KD, Gerngross TU.

Bioconjug Chem. 2011 May 18;22(5):903-12. doi: 10.1021/bc100510g. Epub 2011 Apr 7.

PMID:
21395336
8.

Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.

Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D.

Bioconjug Chem. 2006 May-Jun;17(3):618-30.

PMID:
16704199
9.

Site-specific polymer modification of therapeutic proteins.

Kochendoerfer GG.

Curr Opin Chem Biol. 2005 Dec;9(6):555-60. Epub 2005 Oct 17. Review.

PMID:
16233987
10.

Integration of PEGylation and refolding for renaturation of recombinant proteins from insoluble aggregates produced in bacteria--application to a single-chain Fv fragment.

Kumagai I, Asano R, Nakanishi T, Hashikami K, Tanaka S, Badran A, Sanada H, Umetsu M.

J Biosci Bioeng. 2010 May;109(5):447-52. doi: 10.1016/j.jbiosc.2009.10.016. Epub 2009 Nov 4.

PMID:
20347766
11.

Designing immunoconjugates for cancer therapy.

Govindan SV, Goldenberg DM.

Expert Opin Biol Ther. 2012 Jul;12(7):873-90. doi: 10.1517/14712598.2012.685153. Review.

PMID:
22679911
12.

Designing proteins that work using recombinant technologies.

Graddis TJ, Remmele RL Jr, McGrew JT.

Curr Pharm Biotechnol. 2002 Dec;3(4):285-97. Review.

PMID:
12463413
13.

The impact of PEGylation on biological therapies.

Veronese FM, Mero A.

BioDrugs. 2008;22(5):315-29. Review.

PMID:
18778113
14.
15.

Self-assembled "dock and lock" system for linking payloads to targeting proteins.

Backer MV, Patel V, Jehning BT, Backer JM.

Bioconjug Chem. 2006 Jul-Aug;17(4):912-9.

PMID:
16848397
16.

Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand.

Albrecht H, Burke PA, Natarajan A, Xiong CY, Kalicinsky M, DeNardo GL, DeNardo SJ.

Bioconjug Chem. 2004 Jan-Feb;15(1):16-26.

PMID:
14733579
17.

In vivo selection of intrabodies specifically targeting protein-protein interactions: a general platform for an "undruggable" class of disease targets.

Visintin M, Melchionna T, Cannistraci I, Cattaneo A.

J Biotechnol. 2008 May 20;135(1):1-15. doi: 10.1016/j.jbiotec.2008.02.012. Epub 2008 Mar 4.

PMID:
18395925
18.

Biochemical and immunological properties of cytokines conjugated to dendritic polymers.

Lee SC, Parthasarathy R, Botwin K, Kunneman D, Rowold E, Lange G, Klover J, Abegg A, Zobel J, Beck T, Miller T, Hood W, Monahan J, McKearn JP, Jansson R, Voliva CF.

Biomed Microdevices. 2004 Sep;6(3):191-202.

PMID:
15377828
19.

Recombinant protein scaffolds for tissue engineering.

Werkmeister JA, Ramshaw JA.

Biomed Mater. 2012 Feb;7(1):012002. doi: 10.1088/1748-6041/7/1/012002. Epub 2012 Jan 20. Review.

PMID:
22262725
20.

Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.

Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Wang Y, Chang CH.

Cancer Res. 2008 Oct 15;68(20):8384-92. doi: 10.1158/0008-5472.CAN-08-2033.

Supplemental Content

Support Center